Share Article
- Product Sales of
- Diluted EPS of
- Non-GAAP Diluted EPS of
- Revised Full Year 2018 Guidance -
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| (In millions, except per share amounts) | 2018 | 2017 | 2018 | 2017 | ||||||||
| Product sales | $ | 5,455 | $ | 6,402 | $ | 15,996 | $ | 19,825 | ||||
| Royalty, contract and other revenues | 141 | 110 | 336 | 333 | ||||||||
| Total revenues | $ | 5,596 | $ | 6,512 | $ | 16,332 | $ | 20,158 | ||||
| Net income attributable to Gilead | $ | 2,097 | $ | 2,718 | $ | 5,452 | $ | 8,493 | ||||
| Non-GAAP net income | $ | 2,403 | $ | 2,990 | $ | 6,855 | $ | 9,311 | ||||
| Diluted earnings per share | $ | 1.60 | $ | 2.06 | $ | 4.15 | $ | 6.44 | ||||
| Non-GAAPdiluted earnings per share | $ | 1.84 | $ | 2.27 | $ | 5.22 | $ | 7.06 | ||||
Product Sales
Total product sales for the third quarter of 2018 were
___________________________________
Note: Non-GAAP financial information excludes acquisition-related, up-front collaboration, stock-based compensation and other expenses, fair value adjustments of marketable equity securities and measurement period adjustments relating to the enactment of the 2017 Tax Cuts and Jobs Act (Tax Reform). A reconciliation between GAAP and non-GAAP financial information is provided in the tables on page 7, 8 and 9.
- HIV product sales(1) were
$3.7 billion for the third quarter of 2018 compared to$3.3 billion for the same period in 2017. The increase was primarily due to the continued uptake of products containing emtricitabine (FTC) and tenofovir alafenamide (TAF), which include Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg), Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg), Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) and Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg). - Chronic hepatitis C (HCV) product sales, which consist of
Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), Harvoni®
(ledipasvir 90 mg/sofosbuvir 400 mg), Vosevi®
(sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) and Sovaldi®
(sofosbuvir 400 mg), were
$902 million for the third quarter of 2018 compared to$2.2 billion for the same period in 2017. The decline was primarily due to lower sales of Harvoni and Epclusa across all major markets as a result of increased competition. - Yescarta® (axicabtagene ciloleucel), which
was launched in
the United States inOctober 2017 , generated$75 million in sales during the third quarter of 2018. -
Other product sales, which include products from Gilead’s chronic
hepatitis B (HBV), cardiovascular, oncology and other categories
inclusive of Vemlidy® (tenofovir alafenamide 25 mg), Viread®
(tenofovir disoproxil fumarate 300 mg), Letairis®
(ambrisentan 5 mg and 10 mg), Ranexa® (ranolazine 500 mg
and 1000 mg), Zydelig® (idelalisib 150 mg) and AmBisome®
(amphotericin B liposome for injection 50 mg/vial), were
$751 million for the third quarter of 2018 compared to$874 million for the same period in 2017.
Operating Expenses
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| (In millions) | 2018 | 2017 | 2018 | 2017 | ||||||||
| Research and development expenses (R&D) | $ | 939 | $ | 789 | $ | 3,068 | $ | 2,584 | ||||
| Non-GAAP R&D expenses | $ | 844 | $ | 745 | $ | 2,579 | $ | 2,446 | ||||
| Selling, general and administrative expenses (SG&A) | $ | 948 | $ | 879 | $ | 2,925 | $ | 2,626 | ||||
| Non-GAAP SG&A expenses | $ | 852 | $ | 806 | $ | 2,576 | $ | 2,440 | ||||
During the third quarter of 2018, compared to the same period in 2017:
-
R&D and SG&A expenses increased primarily due to higher costs to
support the growth of Gilead’s business following the acquisition of
Kite Pharma, Inc. (Kite) and stock-based compensation expenses associated with Gilead’s acquisition of Kite. - Non-GAAP R&D and non-GAAP SG&A expenses increased primarily due to higher costs to support the growth of Gilead’s business following the acquisition of Kite.
Cash,
As of
___________________________________
(1) Excludes sales of Viread as Viread is primarily used for treatment of chronic HBV.
Revised Full Year 2018 Guidance
Gilead revised its full year 2018 guidance, initially provided on
| (In millions, except percentages and per share amounts) | Initially ProvidedFebruary 6, 2018 Reiterated May 1, 2018 | Updated July 25, 2018 | Updated October 25, 2018 |
| Net Product Sales | $20,000 - $21,000 | $20,000 - $21,000 | $20,800 - $21,300 |
| Non-GAAP | |||
| Product Gross Margin | 85% - 87% | 85% - 87% | 85% - 87% |
| R&D Expenses | $3,400 - $3,600 | $3,400 - $3,600 | $3,400 - $3,600 |
| SG&A Expenses | $3,400 - $3,600 | $3,400 - $3,600 | $3,400 - $3,600 |
| Effective Tax Rate | 21.0% - 23.0% | 19.0% - 21.0% | 18.0% - 20.0% |
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses | $1.41 - $1.51 | $1.50 - $1.60 | $1.50 - $1.60 |
Corporate Highlights
-
Announced that
John F. Milligan , Ph.D., will step down as President and Chief Executive Officer (CEO). John C. Martin , Ph.D., announced his intent to step down from the Board at the time a new CEO joins the company.-
Announced plans to launch authorized generic versions of Epclusa and
Harvoni in
the United States through a newly created subsidiary,Asegua Therapeutics LLC . - Announced that Laura Hamill has joined the company as Executive Vice President, Worldwide Commercial Operations.
-
Announced that
Gregg Alton has been appointed Chief Patient Officer and thatDiana Brainard , M.D., has been promoted to Senior Vice President, HIV and Emerging Viral Infections. Also announced thatAndrew Cheng , M.D., Ph.D., Chief Medical Officer, decided to leave Gilead to pursue another opportunity. -
Announced that
Michael Amoroso has joined the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy.
Product and Pipeline Updates announced by Gilead during the Third Quarter of 2018 include:
HIV and Liver Diseases Programs
- Announced a strategic collaboration with Precision BioSciences (Precision) to develop therapies targeting the in vivo elimination of HBV virus with Precision’s proprietary genome editing platform, ARCUS.
-
Announced that the
China National Drug Administration has approved Genvoya for the treatment of HIV-1 infection. -
Presented data at the 22nd
International AIDS Conference , which included the announcement of a retrospective nationwide analysis of the impact of Truvada® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg) for pre-exposure prophylaxis (PrEP) use across all 50 U.S. states and theDistrict of Columbia . Conducted in collaboration with researchers atEmory University Rollins School of Public Health and theCenters for Disease Control and Prevention , these data demonstrated that use of once-daily oral Truvada for PrEP has had an independent and significant impact on the number of new HIV infections diagnosed inthe United States from 2012 to 2016.
Oncology and Cell Therapy Programs
-
Announced a license agreement with
Trianni, Inc. (Trianni) that grants Gilead the use of the Trianni transgenic human monoclonal antibody discovery platform to support drug discovery efforts. -
Announced that the
European Commission has granted Marketing Authorization for Yescarta as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy. -
Announced a strategic collaboration with
Gadeta B.V. (Gadeta) to develop novel gamma delta T cell receptor therapies in various cancers.
Inflammation Programs
-
Announced that FINCH 2, a global, randomized, placebo-controlled,
Phase 3 study of filgotinib, an investigational, selective JAK1
inhibitor, in adults with moderately-to-severely active rheumatoid
arthritis and prior inadequate response/intolerance to biologic
agents, achieved its primary endpoint in the proportion of patients
achieving an
American College of Rheumatology 20 percent response at week 12. - Announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis (AS). In the study, patients treated with filgotinib achieved significantly greater improvements in AS Disease Activity Score, the primary endpoint, at week 12, with a mean change from baseline of -1.5 versus -0.6 for those treated with placebo (p
Non-GAAP Financial Information
The information presented in this document has been prepared by Gilead in accordance with U.S. generally accepted accounting principles (GAAP), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 7, 8 and 9.
Conference Call
At
A replay of the webcast will be archived on the company’s website for
one year and a phone replay will be available approximately two hours
following the call through
About
Forward-looking Statements
Statements included in this press release that are not historical in
nature are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Gilead cautions readers that
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: Gilead’s ability to achieve its
anticipated full year 2018 financial results; Gilead’s ability to
sustain growth in revenues for its antiviral and other programs; the
risk that private and public payers may be reluctant to provide, or
continue to provide, coverage or reimbursement for new products,
including Yescarta, Biktarvy and Vemlidy; austerity measures in European
countries that may increase the amount of discount required on Gilead’s
products; an increase in discounts, chargebacks and rebates due to
ongoing contracts and future negotiations with commercial and government
payers; a larger than anticipated shift in payer mix to more highly
discounted payer segments and geographic regions and decreases in
treatment duration; availability of funding for state AIDS Drug
Assistance Programs (ADAPs); continued fluctuations in ADAP purchases
driven by federal and state grant cycles which may not mirror patient
demand and may cause fluctuations in Gilead’s earnings; market share and
price erosion caused by the introduction of generic versions of Viread
and Truvada, an uncertain global macroeconomic environment; and
potential amendments to the Affordable Care Act or other government
action that could have the effect of lowering prices or reducing the
number of insured patients; Gilead’s ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by
wholesalers and retailers which may cause fluctuations in Gilead’s
earnings; Gilead’s ability to develop products utilizing Precision’s
ARCUS platform and Trianni’s transgenic human monoclonal antibody
platform; Gilead’s ability to develop products under its collaboration
with Gadeta; Gilead’s ability to submit new drug applications for new
product candidates in the timelines currently anticipated; Gilead’s
ability to receive regulatory approvals in a timely manner or at all,
for new and current products; Gilead’s ability to successfully
commercialize its products, including Biktarvy and Yescarta; the risk
that physicians and patients may not see advantages of these products
over other therapies and may therefore be reluctant to prescribe the
products; safety and efficacy data from clinical studies may not warrant
further development of Gilead’s product candidates, including
filgotinib; Gilead’s ability to pay dividends or complete its share
repurchase program due to changes in its stock price, corporate or other
market conditions; fluctuations in the foreign exchange rate of the U.S.
dollar that may cause an unfavorable foreign currency exchange impact on
Gilead’s future revenues and pre-tax earnings; and other risks
identified from time to time in Gilead’s reports filed with the
All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.
Gilead owns or has rights to various trademarks, copyrights and trade
names used in its business, including the following: GILEAD®,
LEXISCAN® is a registered trademark of
For more information on
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (in millions, except per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales | $ | 5,455 | $ | 6,402 | $ | 15,996 | $ | 19,825 | ||||||||
| Royalty, contract and other revenues | 141 | 110 | 336 | 333 | ||||||||||||
| Total revenues | 5,596 | 6,512 | 16,332 | 20,158 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of goods sold | 1,086 | 1,032 | 3,283 | 3,115 | ||||||||||||
| Research and development expenses | 939 | 789 | 3,068 | 2,584 | ||||||||||||
| Selling, general and administrative expenses | 948 | 879 | 2,925 | 2,626 | ||||||||||||
| Total costs and expenses | 2,973 | 2,700 | 9,276 | 8,325 | ||||||||||||
| Income from operations | 2,623 | 3,812 | 7,056 | 11,833 | ||||||||||||
| Interest expense | (264 | ) | (291 | ) | (820 | ) | (821 | ) | ||||||||
| Other income (expense), net | 305 | 150 | 547 | 391 | ||||||||||||
| Income before provision for income taxes | 2,664 | 3,671 | 6,783 | 11,403 | ||||||||||||
| Provision for income taxes | 565 | 959 | 1,326 | 2,923 | ||||||||||||
| Net income | 2,099 | 2,712 | 5,457 | 8,480 | ||||||||||||
| Net income (loss) attributable to noncontrolling interest | 2 | (6 | ) | 5 | (13 | ) | ||||||||||
| Net income attributable to Gilead | $ | 2,097 | $ | 2,718 | $ | 5,452 | $ | 8,493 | ||||||||
| Net income per share attributable to Gilead common stockholders - basic | $ | 1.62 | $ | 2.08 | $ | 4.19 | $ | 6.50 | ||||||||
| Shares used in per share calculation - basic | 1,296 | 1,306 | 1,302 | 1,307 | ||||||||||||
| Net income per share attributable to Gilead common stockholders - diluted | $ | 1.60 | $ | 2.06 | $ | 4.15 | $ | 6.44 | ||||||||
| Shares used in per share calculation - diluted | 1,307 | 1,319 | 1,313 | 1,319 | ||||||||||||
| Cash dividends declared per share | $ | 0.57 | $ | 0.52 | $ | 1.71 | $ | 1.56 | ||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||
| GAAP cost of goods sold | $ | 1,086 | $ | 1,032 | $ | 3,283 | $ | 3,115 | ||||||||
| Acquisition-related – amortization of purchased intangibles | (301 | ) | (209 | ) | (902 | ) | (629 | ) | ||||||||
| Stock-based compensation expenses(1) | (15 | ) | (4 | ) | (49 | ) | (12 | ) | ||||||||
| Other(2) | 1 | 2 | 1 | (18 | ) | |||||||||||
| Non-GAAP cost of goods sold | $ | 771 | $ | 821 | $ | 2,333 | $ | 2,456 | ||||||||
| Product gross margin reconciliation: | ||||||||||||||||
| GAAP product gross margin | 80.1 | % | 83.9 | % | 79.5 | % | 84.3 | % | ||||||||
| Acquisition-related – amortization of purchased intangibles | 5.5 | % | 3.3 | % | 5.6 | % | 3.2 | % | ||||||||
| Stock-based compensation expenses(1) | 0.3 | % | — | % | 0.3 | % | — | % | ||||||||
| Other(2) | — | % | — | % | — | % | 0.1 | % | ||||||||
| Non-GAAP product gross margin(4) | 85.9 | % | 87.2 | % | 85.4 | % | 87.6 | % | ||||||||
| Research and development expenses reconciliation: | ||||||||||||||||
| GAAP research and development expenses | $ | 939 | $ | 789 | $ | 3,068 | $ | 2,584 | ||||||||
| Up-front collaboration expenses | — | — | (160 | ) | — | |||||||||||
| Acquisition-related – other costs | 3 | — | (22 | ) | — | |||||||||||
| Stock-based compensation expenses(1) | (99 | ) | (53 | ) | (304 | ) | (142 | ) | ||||||||
| Other(2) | 1 | 9 | (3 | ) | 4 | |||||||||||
| Non-GAAP research and development expenses | $ | 844 | $ | 745 | $ | 2,579 | $ | 2,446 | ||||||||
| Selling, general and administrative expenses reconciliation: | ||||||||||||||||
| GAAP selling, general and administrative expenses | $ | 948 | $ | 879 | $ | 2,925 | $ | 2,626 | ||||||||
| Acquisition-related – transaction costs | — | (12 | ) | — | (12 | ) | ||||||||||
| Acquisition-related – other costs | (8 | ) | — | (23 | ) | — | ||||||||||
| Stock-based compensation expenses(1) | (84 | ) | (56 | ) | (317 | ) | (150 | ) | ||||||||
| Other(2) | (4 | ) | (5 | ) | (9 | ) | (24 | ) | ||||||||
| Non-GAAP selling, general and administrative expenses | $ | 852 | $ | 806 | $ | 2,576 | $ | 2,440 | ||||||||
| Operating margin reconciliation: | ||||||||||||||||
| GAAP operating margin | 46.9 | % | 58.5 | % | 43.2 | % | 58.7 | % | ||||||||
| Up-front collaboration expenses | — | % | — | % | 1.0 | % | — | % | ||||||||
| Acquisition-related – amortization of purchased intangibles | 5.4 | % | 3.2 | % | 5.5 | % | 3.1 | % | ||||||||
| Acquisition-related – transaction costs | — | % | 0.2 | % | — | % | 0.1 | % | ||||||||
| Acquisition-related – other costs | 0.1 | % | — | % | 0.3 | % | — | % | ||||||||
| Stock-based compensation expenses(1) | 3.5 | % | 1.7 | % | 4.1 | % | 1.5 | % | ||||||||
| Other(2) | — | % | (0.1 | )% | 0.1 | % | 0.2 | % | ||||||||
| Non-GAAP operating margin(4) | 55.9 | % | 63.6 | % | 54.2 | % | 63.6 | % | ||||||||
| Interest expense reconciliation: | ||||||||||||||||
| GAAP interest expense | $ | (264 | ) | $ | (291 | ) | $ | (820 | ) | $ | (821 | ) | ||||
| Acquisition-related – transaction costs | — | 18 | — | 18 | ||||||||||||
| Non-GAAP interest expense | $ | (264 | ) | $ | (273 | ) | $ | (820 | ) | $ | (803 | ) | ||||
| Other income (expense), net reconciliation: | ||||||||||||||||
| GAAP other income (expense), net | $ | 305 | $ | 150 | $ | 547 | $ | 391 | ||||||||
| Unrealized gains from marketable equity securities(3) | (168 | ) | — | (149 | ) | — | ||||||||||
| Non-GAAP other income (expense), net | $ | 137 | $ | 150 | $ | 398 | $ | 391 | ||||||||
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) (in millions, except percentages and per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Effective tax rate reconciliation: | ||||||||||||||||
| GAAP effective tax rate | 21.2 | % | 26.1 | % | 19.5 | % | 25.6 | % | ||||||||
| Up-front collaboration expenses | — | % | — | % | 0.1 | % | — | % | ||||||||
| Acquisition-related – amortization of purchased intangibles | (1.5 | )% | (1.2 | )% | (1.5 | )% | (1.2 | )% | ||||||||
| Stock-based compensation expenses(1) | (1.0 | )% | 0.8 | % | (0.1 | )% | 0.6 | % | ||||||||
| Unrealized gains from marketable equity securities(3) | 1.3 | % | — | % | 0.4 | % | — | % | ||||||||
| Tax Reform adjustments | — | % | — | % | 0.1 | % | — | % | ||||||||
| Non-GAAP effective tax rate(4) | 19.9 | % | 25.7 | % | 18.5 | % | 25.0 | % | ||||||||
| Net income attributable to Gilead reconciliation: | ||||||||||||||||
| GAAP net income attributable to Gilead | $ | 2,097 | $ | 2,718 | $ | 5,452 | $ | 8,493 | ||||||||
| Up-front collaboration expenses | — | — | 125 | — | ||||||||||||
| Acquisition-related – amortization of purchased intangibles | 281 | 201 | 843 | 605 | ||||||||||||
| Acquisition-related – transaction costs | — | 24 | — | 24 | ||||||||||||
| Acquisition-related – other costs | 4 | — | 36 | — | ||||||||||||
| Stock-based compensation expenses(1) | 184 | 55 | 546 | 161 | ||||||||||||
| Unrealized gains from marketable equity securities(3) | (164 | ) | — | (146 | ) | — | ||||||||||
| Tax Reform adjustments | — | — | (10 | ) | — | |||||||||||
| Other(2) | 1 | (8 | ) | 9 | 28 | |||||||||||
| Non-GAAP net income attributable to Gilead | $ | 2,403 | $ | 2,990 | $ | 6,855 | $ | 9,311 | ||||||||
| Diluted earnings per share reconciliation: | ||||||||||||||||
| GAAP diluted earnings per share | $ | 1.60 | $ | 2.06 | $ | 4.15 | $ | 6.44 | ||||||||
| Up-front collaboration expenses | — | — | 0.10 | — | ||||||||||||
| Acquisition-related – amortization of purchased intangibles | 0.21 | 0.15 | 0.64 | 0.46 | ||||||||||||
| Acquisition-related – transaction costs | — | 0.02 | — | 0.02 | ||||||||||||
| Acquisition-related – other costs | — | — | 0.03 | — | ||||||||||||
| Stock-based compensation expenses(1) | 0.14 | 0.04 | 0.42 | 0.12 | ||||||||||||
| Unrealized gains from marketable equity securities(3) | (0.13 | ) | — | (0.11 | ) | — | ||||||||||
| Tax Reform adjustments | — | — | (0.01 | ) | — | |||||||||||
| Other(2) | — | (0.01 | ) | 0.01 | 0.02 | |||||||||||
| Non-GAAP diluted earnings per share(4) | $ | 1.84 | $ | 2.27 | $ | 5.22 | $ | 7.06 | ||||||||
| Non-GAAP adjustment summary: | ||||||||||||||||
| Cost of goods sold adjustments | $ | 315 | $ | 211 | $ | 950 | $ | 659 | ||||||||
| Research and development expenses adjustments | 95 | 44 | 489 | 138 | ||||||||||||
| Selling, general and administrative expenses adjustments | 96 | 73 | 349 | 186 | ||||||||||||
| Interest expense adjustments | — | 18 | — | 18 | ||||||||||||
| Other income (expense), net adjustments | (168 | ) | — | (149 | ) | — | ||||||||||
| Total non-GAAP adjustments before tax | 338 | 346 | 1,639 | 1,001 | ||||||||||||
| Income tax effect | (32 | ) | (74 | ) | (226 | ) | (183 | ) | ||||||||
| Tax Reform adjustments | — | — | (10 | ) | — | |||||||||||
| Total non-GAAP adjustments after tax | $ | 306 | $ | 272 | $ | 1,403 | $ | 818 | ||||||||
| Notes: | |
(1) | Stock-based compensation expenses for the three and nine months ended September 30, 2018 include $63 million and $323 million, respectively, associated with Gilead’s acquisition of Kite |
(2) | Amounts represent restructuring, contingent consideration and/or other individually insignificant amounts |
(3) | Amounts represent fair value adjustments of marketable equity securities recorded in Other income (expense), net, on Gilead’s Condensed Consolidated Statements of Income as a result of the adoption of Accounting Standards Update No. 2016-01 “Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” in 2018 |
(4) | Amounts may not sum due to rounding |
GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2018 FULL YEAR GUIDANCE (unaudited) (in millions, except percentages and per share amounts) | ||||
| Initially ProvidedFebruary 6, 2018 Reiterated May 1, 2018 | Updated July 25, 2018 Reiterated October 25, 2018 | |||
| Projected product gross margin GAAP to non-GAAP reconciliation: | ||||
| GAAP projected product gross margin | 78% - 80% | 78% - 80% | ||
| Acquisition-related expenses | 7% - 7% | 7% - 7% | ||
| Non-GAAP projected product gross margin(1) | 85% - 87% | 85% - 87% | ||
| Projected research and development expenses GAAP to non-GAAP reconciliation: | ||||
| GAAP projected research and development expenses | $3,785 - $4,050 | $3,965 - $4,260 | ||
| Stock-based compensation expenses(2) | (315) - (350) | (365) - (400) | ||
| Acquisition-related expenses / up-front collaboration expenses | (70) - (100) | (200) - (260) | ||
| Non-GAAP projected research and development expenses | $3,400 - $3,600 | $3,400 - $3,600 | ||
| Projected selling, general and administrative expenses GAAP to non-GAAP reconciliation: | ||||
| GAAP projected selling, general and administrative expenses | $3,865 - $4,110 | $3,835 - $4,080 | ||
| Stock-based compensation expenses(2) | (425) - (450) | (395) - (420) | ||
| Acquisition-related expenses | (40) - (60) | (40) - (60) | ||
| Non-GAAP projected selling, general and administrative expenses | $3,400 - $3,600 | $3,400 - $3,600 | ||
| Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses(3): | ||||
| Stock-based compensation expenses(2) | $0.50 - $0.56 | $0.50 - $0.54 | ||
| Acquisition-related expenses / up-front collaboration expenses | $0.91 - $0.95 | $1.00 - $1.06 | ||
| Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses(3) | $1.41 - $1.51 | $1.50 - $1.60 | ||
| Notes: | |
(1) | Stock-based compensation expenses have a less than one percent impact on non-GAAP projected product gross margin |
(2) | Includes stock-based compensation expenses associated with Gilead’s acquisition of Kite |
(3) | Excludes fair value adjustments of marketable equity securities, as Gilead is unable to project future fair value adjustments, and measurement period adjustments during 2018 relating to Tax Reform. Gilead is unable to project an effective tax rate on a GAAP basis |
GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions) | |||||||
| September 30, | December 31, | ||||||
| 2018 | 2017 | ||||||
| Cash, cash equivalents and marketable securities | $ | 30,844 | $ | 36,694 | |||
| Accounts receivable, net | 3,465 | 3,851 | |||||
| Inventories | 816 | 801 | |||||
| Property, plant and equipment, net | 3,791 | 3,295 | |||||
| Intangible assets, net | 16,314 | 17,100 | |||||
| Goodwill | 4,117 | 4,159 | |||||
| Other assets | 4,958 | 4,383 | |||||
| Total assets | $ | 64,305 | $ | 70,283 | |||
| Current liabilities | $ | 10,116 | $ | 11,635 | |||
| Long-term liabilities | 31,182 | 38,147 | |||||
| Stockholders’ equity(1) | 23,007 | 20,501 | |||||
| Total liabilities and stockholders’ equity | $ | 64,305 | $ | 70,283 | |||
| Note: | |
(1) | As of September 30, 2018, there were 1,294 million shares of common stock issued and outstanding |
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) (in millions) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| Atripla – U.S. | $ | 221 | $ | 324 | $ | 723 | $ | 974 | |||||||
| Atripla – Europe | 29 | 79 | 119 | 259 | |||||||||||
| Atripla – Other International | 8 | 36 | 79 | 133 | |||||||||||
| 258 | 439 | 921 | 1,366 | ||||||||||||
| Biktarvy – U.S. | 375 | — | 593 | — | |||||||||||
| Biktarvy – Europe | 11 | — | 13 | — | |||||||||||
| Biktarvy – Other International | — | — | — | — | |||||||||||
| 386 | — | 606 | — | ||||||||||||
| Complera / Eviplera – U.S. | 61 | 91 | 210 | 315 | |||||||||||
| Complera / Eviplera – Europe | 67 | 133 | 279 | 385 | |||||||||||
| Complera / Eviplera – Other International | 11 | 13 | 39 | 44 | |||||||||||
| 139 | 237 | 528 | 744 | ||||||||||||
| Descovy – U.S. | 310 | 241 | 895 | 682 | |||||||||||
| Descovy – Europe | 81 | 65 | 234 | 149 | |||||||||||
| Descovy – Other International | 15 | 10 | 41 | 22 | |||||||||||
| 406 | 316 | 1,170 | 853 | ||||||||||||
| Genvoya – U.S. | 921 | 810 | 2,678 | 2,189 | |||||||||||
| Genvoya – Europe | 203 | 146 | 596 | 358 | |||||||||||
| Genvoya – Other International | 52 | 32 | 144 | 67 | |||||||||||
| 1,176 | 988 | 3,418 | 2,614 | ||||||||||||
| Odefsey – U.S. | 323 | 255 | 905 | 688 | |||||||||||
| Odefsey – Europe | 95 | 37 | 230 | 87 | |||||||||||
| Odefsey – Other International | 5 | 4 | 15 | 6 | |||||||||||
| 423 | 296 | 1,150 | 781 | ||||||||||||
| Stribild – U.S. | 111 | 181 | 388 | 632 | |||||||||||
| Stribild – Europe | 20 | 40 | 83 | 161 | |||||||||||
| Stribild – Other International | 15 | 8 | 36 | 38 | |||||||||||
| 146 | 229 | 507 | 831 | ||||||||||||
| Truvada – U.S. | 665 | 604 | 1,821 | 1,635 | |||||||||||
| Truvada – Europe | 62 | 154 | 245 | 527 | |||||||||||
| Truvada – Other International | 30 | 53 | 108 | 175 | |||||||||||
| 757 | 811 | 2,174 | 2,337 | ||||||||||||
| Other HIV(1) – U.S. | 10 | 13 | 30 | 34 | |||||||||||
| Other HIV(1) – Europe | 2 | 2 | 6 | 5 | |||||||||||
| Other HIV(1) – Other International | 2 | — | 10 | 2 | |||||||||||
| 14 | 15 | 46 | 41 | ||||||||||||
| Revenue share – Symtuza(2) – U.S. | 8 | — | 8 | — | |||||||||||
| Revenue share – Symtuza(2) – Europe | 14 | — | 34 | — | |||||||||||
| 22 | — | 42 | — | ||||||||||||
| Total HIV – U.S. | 3,005 | 2,519 | 8,251 | 7,149 | |||||||||||
| Total HIV – Europe | 584 | 656 | 1,839 | 1,931 | |||||||||||
| Total HIV – Other International | 138 | 156 | 472 | 487 | |||||||||||
| $ | 3,727 | $ | 3,331 | $ | 10,562 | $ | 9,567 | ||||||||
GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) (in millions) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||
| AmBisome – U.S. | $ | 9 | $ | 9 | $ | 40 | $ | 26 | |||||||
| AmBisome – Europe | 59 | 51 | 170 | 153 | |||||||||||
| AmBisome – Other International | 34 | 32 | 102 | 97 | |||||||||||
| 102 | 92 | 312 | 276 | ||||||||||||
| Epclusa – U.S. | 225 | 543 | 733 | 2,142 | |||||||||||
| Epclusa – Europe | 136 | 263 | 502 | 649 | |||||||||||
| Epclusa – Other International | 116 | 76 | 278 | 154 | |||||||||||
| 477 | 882 | 1,513 | 2,945 | ||||||||||||
| Harvoni – U.S. | 185 | 718 | 649 | 2,628 | |||||||||||
| Harvoni – Europe | 38 | 110 | 116 | 583 | |||||||||||
| Harvoni – Other International | 88 | 145 | 225 | 515 | |||||||||||
| 311 | 973 | 990 | 3,726 | ||||||||||||
| Letairis – U.S. | 241 | 213 | 689 | 654 | |||||||||||
| Ranexa – U.S. | 178 | 164 | 581 | 517 | |||||||||||
| Vemlidy – U.S. | 66 | 34 | 172 | 66 | |||||||||||
| Vemlidy – Europe | 2 | 2 | 8 | 3 | |||||||||||
| Vemlidy – Other International | 19 | 1 | 41 | 1 | |||||||||||
| 87 | 37 | 221 | 70 | ||||||||||||
| Viread – U.S. | 17 | 137 | 40 | 395 | |||||||||||
| Viread – Europe | 10 | 55 | 72 | 202 | |||||||||||
| Viread – Other International | 43 | 82 | 137 | 237 | |||||||||||
| 70 | 274 | 249 | 834 | ||||||||||||
| Vosevi – U.S. | 78 | 117 | 250 | 117 | |||||||||||
| Vosevi – Europe | 21 | 5 | 57 | 5 | |||||||||||
| Vosevi – Other International | 4 | 1 | 12 | 1 | |||||||||||
| 103 | 123 | 319 | 123 | ||||||||||||
| Yescarta – U.S. | 75 | — | 183 | — | |||||||||||
| Zydelig – U.S. | 15 | 18 | 46 | 52 | |||||||||||
| Zydelig – Europe | 4 | 22 | 44 | 57 | |||||||||||
| Zydelig – Other International | 1 | — | 2 | 1 | |||||||||||
| 20 | 40 | 92 | 110 | ||||||||||||
| Other(3) – U.S. | 37 | 70 | 93 | 228 | |||||||||||
| Other(3) – Europe | 19 | 33 | 75 | 279 | |||||||||||
| Other(3) – Other International | 8 | 170 | 117 | 496 | |||||||||||
| 64 | 273 | 285 | 1,003 | ||||||||||||
| Total product sales – U.S. | 4,131 | 4,542 | 11,727 | 13,974 | |||||||||||
| Total product sales – Europe | 873 | 1,197 | 2,883 | 3,862 | |||||||||||
| Total product sales – Other International | 451 | 663 | 1,386 | 1,989 | |||||||||||
| $ | 5,455 | $ | 6,402 | $ | 15,996 | $ | 19,825 | ||||||||
| Notes: | |
(1) | Includes Emtriva and Tybost |
(2) | Represents Gilead’s revenue from cobicistat (C), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen |
(3) | Includes Cayston, Hepsera and Sovaldi |
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005978/en/
Source:
Gilead Sciences, Inc.InvestorsRobin Washington, 650-522-5688Sung Lee, 650-524-7792orMediaAmy Flood, 650-522-5643
Other News
Some of the content on this page is not intended for users outside the U.S.